Abstract：Objective To explore the effect of Apatinib combined with Paclitaxel in the second-line treatment of Her-2 negative advanced gastric cancer patients. Methods A total of 96 patients with Her-2 negative advanced gastric cancer who were treated at Shangrao People′s Hospital in Jiangxi from January 2018 to January 2021 were selected as the subjects of this study, and they were divided into the control group and the study group by simple randomization method, with 48 cases in each group. Patients in the control group were treated with Paclitaxel alone, and patients in the study group were treated with Apatinib combined with Paclitaxel as second-line treatment. The clinical efficacy,adverse reactions and progression-free survival time of the two groups of patients were compared. Results The total effective rate, disease control rate in the study group after treatment were higher than those in the control group, and progression-free survival time of the patients in the study group after treatment was longer than that in the control group,the differences were statistically significant (P<0.05). There was no significant difference in the total incidence of adverse reactions between the two groups (P>0.05). Conclusion The second-line treatment of Apatinib combined with Paclitaxel can significantly improve the clinical efficacy of HER-2 negative patients with advanced gastric cancer, effectively prolong the progression free survival time, and is conducive to the control of the disease. At the same time, there is a certain degree of safety and no serious adverse situation. It is worthy of widespread clinical promotion.
韩永清； 傅峰； 黄开荣. 阿帕替尼联合紫杉醇二线治疗在Her-2阴性晚期胃癌患者中的应用效果[J]. 中国当代医药, 2022, 29(8): 83-85转90.
HAN Yongqing； FU Feng； HUANG Kairong. Efficacy and safety of second-line treatment with Apatinib and Paclitaxel for HER-2 negative advanced gastric cancer. 中国当代医药, 2022, 29(8): 83-85转90.
京公网安备 11010502046607号